Can-Fite BioPharma (CANF) Competitors $1.04 0.00 (0.00%) Closing price 03:59 PM EasternExtended Trading$1.03 -0.01 (-0.96%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CANF vs. HOOK, NEUP, ERNA, SYBX, BFRG, MTVA, BCTX, LPTX, TXMD, and NKGNShould you be buying Can-Fite BioPharma stock or one of its competitors? The main competitors of Can-Fite BioPharma include HOOKIPA Pharma (HOOK), Neuphoria Therapeutics (NEUP), Ernexa Therapeutics (ERNA), Synlogic (SYBX), Bullfrog AI (BFRG), MetaVia (MTVA), Briacell Therap (BCTX), Leap Therapeutics (LPTX), TherapeuticsMD (TXMD), and NKGen Biotech (NKGN). These companies are all part of the "pharmaceutical products" industry. Can-Fite BioPharma vs. Its Competitors HOOKIPA Pharma Neuphoria Therapeutics Ernexa Therapeutics Synlogic Bullfrog AI MetaVia Briacell Therap Leap Therapeutics TherapeuticsMD NKGen Biotech Can-Fite BioPharma (NYSE:CANF) and HOOKIPA Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations. Do analysts prefer CANF or HOOK? Can-Fite BioPharma currently has a consensus price target of $14.00, indicating a potential upside of 1,239.71%. HOOKIPA Pharma has a consensus price target of $4.50, indicating a potential upside of 294.74%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Can-Fite BioPharma is more favorable than HOOKIPA Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00HOOKIPA Pharma 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media prefer CANF or HOOK? In the previous week, HOOKIPA Pharma's average media sentiment score of 1.89 beat Can-Fite BioPharma's score of 0.00 indicating that HOOKIPA Pharma is being referred to more favorably in the news media. Company Overall Sentiment Can-Fite BioPharma Neutral HOOKIPA Pharma Very Positive Is CANF or HOOK more profitable? Can-Fite BioPharma has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. Can-Fite BioPharma's return on equity of 0.00% beat HOOKIPA Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Can-Fite BioPharmaN/A N/A N/A HOOKIPA Pharma -785.66%-120.09%-77.14% Which has stronger earnings & valuation, CANF or HOOK? Can-Fite BioPharma has higher earnings, but lower revenue than HOOKIPA Pharma. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than HOOKIPA Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCan-Fite BioPharma$674K5.49-$7.63M-$1.79-0.58HOOKIPA Pharma$43.95M0.32-$43.50M-$5.85-0.19 Which has more risk and volatility, CANF or HOOK? Can-Fite BioPharma has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, HOOKIPA Pharma has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Do insiders & institutionals have more ownership in CANF or HOOK? 21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 63.9% of HOOKIPA Pharma shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by company insiders. Comparatively, 3.3% of HOOKIPA Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryCan-Fite BioPharma beats HOOKIPA Pharma on 10 of the 14 factors compared between the two stocks. Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CANF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CANF vs. The Competition Export to ExcelMetricCan-Fite BioPharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3.70M$760.57M$5.50B$20.79BDividend YieldN/A4.84%4.25%3.67%P/E Ratio-0.581.3928.1027.50Price / Sales5.4925.51380.1585.29Price / CashN/A19.5635.5321.88Price / Book0.596.728.264.66Net Income-$7.63M-$4.32M$3.24B$994.58M7 Day Performance0.97%0.00%0.50%-0.69%1 Month Performance-0.48%1.41%7.99%5.41%1 Year Performance-71.29%-1.96%28.68%9.18% Can-Fite BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CANFCan-Fite BioPharma2.3881 of 5 stars$1.05flat$14.00+1,239.7%-71.4%$3.70M$674K-0.588HOOKHOOKIPA Pharma3.0849 of 5 stars$1.20+0.8%$4.50+275.0%-82.7%$14.63M$43.95M-0.21160Positive NewsNEUPNeuphoria Therapeutics2.2354 of 5 stars$7.70+0.1%$21.00+172.7%N/A$14.48M$15.66M0.00N/ANews CoverageERNAErnexa Therapeutics0.5784 of 5 stars$1.96+0.5%N/A-93.7%$14.44M$535K-0.2410SYBXSynlogic0.993 of 5 stars$1.23+1.2%N/A-3.2%$14.33M$10K-0.4980Positive NewsBFRGBullfrog AI0.717 of 5 stars$1.51flatN/A-50.7%$14.22M$60K-1.864MTVAMetaVia1.7358 of 5 stars$0.71-1.1%$7.50+956.5%N/A$13.91MN/A0.008BCTXBriacell Therap1.8852 of 5 stars$2.02flat$32.00+1,484.2%-94.4%$13.69MN/A-0.248LPTXLeap Therapeutics2.2429 of 5 stars$0.33+0.1%$3.38+922.4%-84.4%$13.68MN/A-0.1940Positive NewsTXMDTherapeuticsMD0.2574 of 5 stars$1.17-0.8%N/A-38.5%$13.54M$1.76M0.00420News CoverageNKGNNKGen Biotech0.2619 of 5 stars$0.30+0.3%N/A-71.0%$13.53MN/A-0.06N/ANews CoverageGap Up Related Companies and Tools Related Companies HOOKIPA Pharma Alternatives Neuphoria Therapeutics Alternatives Ernexa Therapeutics Alternatives Synlogic Alternatives Bullfrog AI Alternatives MetaVia Alternatives Briacell Therap Alternatives Leap Therapeutics Alternatives TherapeuticsMD Alternatives NKGen Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CANF) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CANF Stock Alerts